Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Inclusion Criteria: * Patient must be able to understand and willing to sign an IRB approved written informed consent document. * Patient must have histologically or cytologically confirmed pancreatic adenocarcinoma, which is locally advanced, unresectable, or metastatic. * Patient must have received no previous surgery, chemotherapy, radiotherapy or investigational therapy for the treatment of locally advanced or metastatic disease. * If a patient has had adjuvant/neoadjuvant therapy for localized disease, tumor recurrence or disease progression must have occurred no sooner than 6 months after completing the last dose of the aforementioned therapies. * Patient must have radiographically measurable disease according to RECIST 1.1 * Patient must be \> 18 years of age. * Patient must have a life expectancy of \>= 3 months. * Patient must have an ECOG performance status ≤ 1. * Patient must have normal bone marrow and organ function as defined below: * Absolute neutrophil count \>=1,500/mcl * Platelets \>=100,000/mcl * Hemoglobin \>=9.0 g/dL * Serum Albumin \>=3.0 g/dL * Creatinine should be below the upper limit of normal OR Creatinine clearance (eGFR) \>=60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal * Plasma antithrombin III \>= 65%, fibrinogen \>= 150 mg/dL, international normalized ratio (INR) ≤ 1.5, and partial thromboplastin time (PTT) ≤ institutional ULN. * Total bilirubin ≤ 1.5x institutional ULN * Patients who have had a…